Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death. WHO data show that, in 2018 alone, over 2 million new cases of breast cancer were reported.[1] To identify breast cancer at earlier stages, when treatment can be more successful, screening mammography programs were developed worldwide over the last decades. [2] A European multicentre study conducted by Tabár et al., demonstrated that in 29 years, mammographic screening provided a 30% reduction of breast cancer mortality [3]. While mammography...

Patient population: In this retrospective study, we included 106 patients (age range: 40-75 years), who consecutively underwent digital mammography at our institution from January to December 2015, and whose subsequent work-up or 2-years follow-up was available. No information about the patient population was provided to the readers. Mammograms selection and evaluation: 106 mammograms (MGs) were firstly evaluated by an expert radiologist, with over 20 years’ experience in breast imaging. The same MGs were then retrospectively categorized, according to the BI-RADS lexicon developed by the American...

19/106 MGs were classified as BI-RADS 0 by the expert radiologist and both residents. Among the remaining 87 MGs, according to the standard of reference, 34 were M+ and 53 were M-. With BD4BREAST, both residents (respectively R1 and R2) demonstrated a statistically significant increase in: diagnostic accuracy (93.1% vs 80.5%, 89.7 vs 75.6%; p

In line with the existing literature about CAD and artificial intelligence use for breast cancer detection in mammography, BD4BREAST has proved to be an efficient DSS for the detection and classification of breast mammographic findings according to the BI-RADS criteria, with a great potential to effectively train future breast radiologists, without a significative increase in reading time.

Dr. Giorgia Porrello [email protected] Dr. Alessia Orlando [email protected] Dr. Maria Ilenia Schillaci [email protected] Dr. Mariangela Dimarco [email protected] Dr. Maria Laura Di Vittorio [email protected] Dr. Silvia Busalacchi [email protected] Dr. Eng. Marco Insalaco [email protected] Prof. Salvatore Vitabile [email protected] Prof. Massimo Midiri [email protected] The authors declare that they have nothing to disclose.

1.Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68: 394-424. doi:10.3322/caac.21492 2.McKinney, S.M., Sieniek, M., Godbole, V.et al.International evaluation of an AI system for breast cancer screening.Nature577,89–94 (2020) doi:10.1038/s41586-019-1799-6 3.Tabár L, Vitak B, Chen TH-H, et al. Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades. Radiology. 2011;260(3):658-663. 4.T.M. Kolb, J. Lichy, J.H. Newhouse, Comparison of the performance...